Covaxin shows interim clinical efficacy of 81% in Phase 3 results
Covaxin is one of two Covid vaccines to have been cleared for emergency use approval by the Indian government - the other is Covishield, which has a 70 per cent efficacy after the second dose
Phase 3 results for Bharat Biotech's coronavirus vaccine - Covaxin - were released Wednesday afternoon, with the drug demonstrating "81 per cent interim efficacy in preventing Covid-19 in those without prior infection after the second dose", according to a statement by the company.
"Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints," the company further said, reports the NDTV.
Covaxin is one of two Covid vaccines to have been cleared for emergency use approval by the government - the other is Covishield, which has a 70 per cent efficacy after the second dose.
Keep updated, follow The Business Standard's Google news channel
The decision to green-light Covaxin triggered a row, with critics pointing to a lack of efficacy data at that time.
Covaxin has completed only two of three required trial phases; the third - which tests for efficacy - began in November. The two earlier phases only ensured that the drug is safe.
